



## Eledon Pharmaceuticals Announces Participation in November Conferences

November 4, 2021

IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that members of management will be participating in two upcoming virtual investor conferences in November.

**Event:** Guggenheim 3rd Annual Neuro/Immunology Conference (November 15-16)  
**Format:** 1x1 Meetings

**Event:** Jefferies London Healthcare Conference (November 18-19)  
**Format:** Available on Demand Presentation and 1x1 Meetings  
**Date:** Thursday, November 18, 2021  
**Time:** Available on-demand starting at 3:00 AM ET  
**Location:** [webcast link](#)

### Replay Link:

A replay will be accessible for 90 days following the live session on the Events page of the Investors section on the Company's website at <https://ir.eledon.com/events-and-presentations/events>.

If you are interested in arranging a one-on-one meeting virtually on either November 18<sup>th</sup> or 19<sup>th</sup>, please contact your Jefferies representative. For more information about the *Jefferies London Healthcare Conference*, please visit the Jefferies [conference website](#).

### About Eledon Pharmaceuticals and AT-1501

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at [www.eledon.com](http://www.eledon.com).

Follow Eledon Pharmaceuticals on social media: [LinkedIn](#); [Twitter](#)

### Investor Contact

Corey Davis, Ph.D.  
LifeSci Advisors  
212-915-2577  
[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)



Source: Eledon Pharmaceuticals, Inc.